]>
IRCT20120225009124N3 IRCT 2018-12-24 National Institute for Medical Research Development Colonoscopic screening for colorectal cancer Implementation of a population-level colonoscopic screening in first-degree relatives of colorectal cancer patients in Golestan province of Iran: Feasibility and Effectiveness 2018-04-21 anticipated 1000 Complete https://irct.ir/trial/34900 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Screening. 3 Colorectal cancer. Intervention 1: Intervention group: Colonoscopy. The subjects will receive screening colonoscopic examination. In case of any abnormal pathological findings, appropriate treatment will be considered for the subject. Intervention 2: Control group: No colonoscopy. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Gholamreza Roshandel
Sayyad Shirazi Bolevard, Sayyad Shirazi hospital
Gorgan Iran (Islamic Republic of) 4917867439 +98 17 3225 1910 roshandel_md@yahoo.com Gorgan University of Medical Sciences scientific Gholamreza Roshandel
Sayyad Shirazi Bolevard, Sayyad Shirazi hospital
Gorgan Iran (Islamic Republic of) 4917867439 +98 17 3225 1910 roshandel_md@yahoo.com Gorgan University of Medical Sciences Iran (Islamic Republic of) Having history of colorectal cancer in first degree relative Age lower than 75 no limit 75 years Both Personal history of malignancy Contraindications of colonoscopy Personal history of cirrhosis Personal history of renal failure C18.9 Malignant neoplasm of colon, unspecified Prevention N/A Intervention group: Colonoscopy. The subjects will receive screening colonoscopic examination. In case of any abnormal pathological findings, appropriate treatment will be considered for the subject Control group: No colonoscopy Incidence of Colorectal cancer. Timepoint: 3 years. Method of measurement: All participants in the intervention and control groups will be followed annually. Each subject will annually be contacted by a telephone call, and questions about the subject’s vital status and cancer incidence will be asked. If there is any possible evidence of developing cancer or death in each subject, the follow up team will collect supportive documents (from patient's hospital files,...) to define the exact cause of death or type of cancer. CRC mortality. Timepoint: End of study follow up. Method of measurement: Telephone follow up and confirmation by reviewing patients' documents and files. National Institute for Medical Research Development Approved 2016-10-14 Ethics commiittee of the National Institute for Medical Medical Research Development West Fatemi Tehran Tehran Iran (Islamic Republic of)